

# LATVIA

## Recent and planned developments in pharmaceutical policies 2025

### CHANGES IN PRICING

- Prescription medicinal product (reimbursable and non-reimbursable) manufacturer's price may not exceed the lowest declared price for the product in the Republic of Lithuania or the Republic of Estonia (01.01.2025.)
- The price for all prescription medicines and medicines within the framework of the reimbursement system, including reimbursed unregistered medicines is same.
- Change in mark-ups :
  - wholesaler sells mark-up: *0.50 euros*
  - Pharmacy mark-ups:
 

No. pc .	Wholesale price ( euro )	Correction amount ( euro )
1	up to 2.00	0.5
2	2.01–100.00	1.2
3	over 100.00	2
- The manufacturer may increase the price no more than once in a 12-month period.

### CHANGES IN REIMBURSEMENT

- Fee for the pharmacist's service when first dispensing the medicine: 1.5 euro or 2.50 euro if the pharmacy (pharmacy branch) is the only pharmacy (pharmacy branch) in the specific settlement. (0.75 euro covers 0.75 euros by the purchaser , remaining amount covered by NHS).This amount is fully covered from NHS to children under 18 years of age, needy persons, asylum seekers and Ukrainian civilians specified in the Law on Support for Civilians of Ukraine.
- Increased reimbursable amount for individual compensation from 14 288 euro to 30 000 euro (including VAT) (01.10.2024)
- Parenteral used medicinal product which are included in Positive list but received in day hospitals is provides through hospital pharmacies (01.07.2024.)

### OTHER CHANGES

Please indicate recent and planned changes (please also indicate the status of implementation and dates) related to:

- A fund is being created for Compensation for medicines and medical devices in emergency cases (01.07.2025.)
- Unregistered medicines and M list medicines (for children under 2y and pregnant women, women in the postpartum period up to 70 days) can be subscribed on e-prescription
- All prescription medicinal product should be prescribed on e-prescriptions, only exception is when E-health system is out of order (01.07.2025.)

### SPECIAL TOPIC:

#### Current advances in HTA

(for EU Member States: Implications from EU-HTA Regulation)

- Since 2019 in Latvia HTA is organised and conducted in State Agency of Medicine. In terms of HTA the information from patient organizations and doctors have been collected.
- The pricing and/or reimbursement decisions for all new molecules and patient groups is based on SAM conclusion